<DOC>
	<DOCNO>NCT00066092</DOCNO>
	<brief_summary>This randomize , double-blind , multi-center study ass safety effectiveness use single subcutaneous ( skin ) injection pegfilgrastim daily subcutaneous injection Filgrastim mobilize stem cell autologous transplantation patient Hodgkin 's non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Pegfilgrastim PBPC Mobilization Study</brief_title>
	<detailed_description>This research study Hodgkin 's Disease Non-Hodgkin 's Lymphoma ( NHL ) patient receive high-dose chemotherapy autologous peripheral blood stem cell ( PBSC PBPC ) transplant . The chemotherapy dose high enough severely suppress bone marrow ( blood cell make ) cause low blood count . A collection stem cell ( young blood cell ) follow reinfusion restore blood count do stimulate recovery blood count . This procedure call leukapheresis . Giving growth factor patient method increase number PBPC collect leukapheresis . This process give growth factor patient call mobilization ( move cell bone marrow peripheral blood collect ) . The purpose study determine pegfilgrastim , investigational drug , safely effectively mobilize stem cell . Filgrastim ( also know NEUPOGENÂ® G-CSF ) approve FDA stem cell mobilization . Pegfilgrastim modify version Filgrastim longer act .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Hodgkin 's nonHodgkin 's lymphoma patient suitable autologous PBPC transplant No previous bone marrow PBPC transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>PBPC transplant</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>mobilization</keyword>
</DOC>